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GABAB and GABAA receptors were examined by quantitative [3H]GABA autoradiography in postmor- 
tem human hippocampus from 6 histopathologically verified cases of dementia of the Alzheimer type 
(DAT) and 6 normal controls. Significant decrements in the Bma~ for both types of GABA receptors were 
observed in DAT hippocampus as compared to normal controls. No significant differences in Kd values 
were revealed. As compared to controls, DAT hippocampus exhibited fewer GABAa receptors in stratum 
moleculare of the dentate gyrus, stratum lacunosum-moleculare and stratum pyramidale of CA). Signifi- 
cant loss of GABAA receptors in DAT hippocampus was also observed in the CA) pyramidal cell region. 
These changes could not be correlated with differences in age nor in postmortem delay between the two 
groups. These findings may reflect the neuronal pathologies in CA~ region, in dentate gyrus, and in projec- 
tions from the entorhinal cortex which are associated with the memory impairment in DAT. 
The pathologic hallmarks of dementia of the Alzheimer type (DAT) are most strik- 
ingly evident in the hippocampus. Abundant neurofibrillary tangles, neuritic plaque 
formation [7] and widespread granulovacuolar degeneration are localized in specific 
cell layers of the hippocampus [1]: the CA~ pyramidal fields, entorhinal 
cortical laminae I and IV, and the subiculum. Degeneration of these neuronal elements 
disrupts the multisynaptic circuitry through the hippocampus and serves to isolate 
the hippocampus from its association and limbic connections [9]. This functional 
dissociation of the hippocampus may contribute to the impaired memory formation 
and retrieval seen in dementia of the Alzheimer type (DAT) [20]. 
?-Aminobutyric acid (GABA) is an ubiquitous inhibitory neurotransmitter of 
intrinsic hippocampal non-pyramidal neurons [21]. Several findings implicate the 
participation of GABAergic systems in DAT pathology. The presence of GAD-posi- 
tive immunoreactive terminals in senile plaques suggests that these may represent 
remnants of degenerating GABAergic processes [22]. The findings of reduced synap- 
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tosomal GABA uptake in hippocampus and cortex of  Alzheimer brains are indica- 
tive of  loss of  GABAergic terminals [8]. GABA is also widely co-localized with soma- 
tostatin [19], the markers for which are consistently reduced in DAT [18]. Cerebrospi- 
nal fluid (CSF) concentrations of  GABA are notably lower in DAT patients as com- 
pared to controls [23]. 
GABA exerts synaptic effects via two types of receptors [3]. In hippocampal 
granule or pyramidal cell somata, GABA elicits fast inhibitory postsynaptic poten- 
tials (IPSPs) by increasing chloride influx [2]. These somatic GABAergic responses 
are mediated by bicuculline-sensitive GABAA receptors. Within the dendritic and 
somatic layers of  granule and pyramidal cells, GABA can also cause a bicucuiline- 
insensitive later- onset IPSP by opening K ÷ channels [5]. This effect of  GABA can 
be mimicked by baclofen and involves activation of  a distinct GABAB receptor. 
Previously we have described losses of  baclofen-sensitive GABAB receptors in the 
frontal cortex of  persons who died with Alzheimer's disease [4]. In the present study, 
using quantitative autoradiography, we have compared the distribution and numbers 
of GABAA and GABAB receptors in the hippocampus of individuals who died with 
DAT and of  normal controls who died without neurologic disease: The DAT patients 
died with respiratory complications following 6 or more years of  progressive intellec- 
tual decline and illness. The control cases suffered sudden cardiac arrest or trauma. 
Previous drug history indicated that one DAT patient was taking haloperidol (6 mg/ 
day), another was taking benzodiazepines, and one of  the control subjects was taking 
a calcium channel blocker. At autopsy, the brain was removed and halved in the 
sagittal plane. One half was fixed in formalin for histopathologic identification and 
the other half was retained at - 7 0 ° C  for receptor binding assays. The diagnosis of  
Alzheimer's disease was based on previously defined neuropathologic criteria [11]. 
Blocks of hippocampus from 6 normal control and 6 DAT brains were obtained, 
coded and stored at - 7 0 ° C  until use. Mean age and postmortem delay (PMD) were 
not significantly different between the two groups (mean control age = 55 + 18 years, 
mean DAT age=71__+7 years, mean control P M D = 1 5 . 5 + 7 . 3  h, mean DAT 
PMD = 18.6 + 9.8 h, both non-significant by independent Student's t-test). The DAT 
brains were atrophic (weighing less than 1300 g). Silver-stained sections of  DAT hip- 
pocampus exhibited more than 10 tangles and/or plaques per high-power field. 
Tissue blocks were equilibrated at - 20°C one day before the assay was performed. 
Forty-four 20-/tm-thick sections were cut at - 2 0 ° C  from each block. Sections were 
thaw-mounted onto gelatin/chrom-alum-coated slides and allowed to air-dry. Slides 
were given a 15-min prewash in 50 mM Tris-HCI buffer containing 2.5 mM CaCI2 
(pH 7.40 at 4°C) to remove endogenous GABA, and dried under a stream of  cool 
air. Each slide was then placed in a vial containing [3H]GABA (Amersham, 50 Ci/ 
mmol, Batch 35) with the above buffer and various drug displacers. For  GABAB 
binding, 10 /tM isoguvacine (Cambridge Research Biochemicals, Cambridgeshire, 
U.K.) was present to block binding to GABAA-sensitive sites. This concentration of 
isoguvacine was determined to be optimal for blocking GABAA binding sites without 
affecting GABAB receptor binding. For  GABAA binding, 100 ~m (+)-baclofen 
(kindly donated by CIBA-GEIGY Corporation, Summit, N J) was present to block 
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binding to GABAB-sensitive sites. Non-specific [3H]GABA binding was assessed in 
the presence of both 100/zM (___)-baclofen and 100/tM isoguvacine, to ensure that 
both GABAB and GABAA binding sites were adequately blocked. 
Studies of  saturation binding to GABAB and GABAA receptors were conducted 
using the method of isotopic dilution of [3H]GABA by non-radioactive GABA to 
achieve a range of free GABA concentrations ranging from 6 nM to 1/IM. GABAB 
and GABAA receptor assays each employed 22 sections from each brain examined. 
This permitted l I-point saturation curves with blanks at each concentration point. 
The binding assay was conducted at 4°C for 45 min. After this period slides were 
removed individually and subjected to two quick rinses with cold buffer, followed 
by one rinse with 1.25% glutaraldehyde in acetone, and immediately dried. Slides 
were mounted in an X-ray cassette with the appropriate radioactive standards and 
apposed to LKB tritium-sensitive 3H-Ultrofilm for 3 weeks at 4°C. The standards 
employed are 14C-plastic standards that were previously calibrated against brain 
paste standards containing known amounts of  tritium and protein [15]. Films were 
developed in Kodak D19, fixed and dried. Optical film densities in various regions 
of interest were quantified by spot densitometry relative to the known standards. The 
regions of interest included stratum moleculare of dentate gyrus, stratum lacunosum- 
moleculare of CAI, stratum pyramidale of CAI and subiculum. The autoradio- 
graphic image was compared to a Cresyl violet stain of  the underlying tissue section 
to determine the anatomic regions of interest. Bound values at each concentration 
of GABA in these various regions were quantified in pmol/mg protein. For both 
types of  GABA receptors, Scatchard plots were constructed to generate Bma x and Kd 
values using computer-assisted linear regression. The code was broken and differ- 
ences in Bmax and Kd values between control and DAT groups were analyzed for sig- 
nificance by independent, two-tailed Student's t-test and by Mann-Whitney U-test. 
In the presence of 2.5 mM CaCI2, [3H]GABA bound to human hippocampus in 
a distinct laminar pattern to two populations of receptors isoguvacine-sensitive 
GABAA and baclofen-sensitive GABAB receptors. When both isoguvacine and bac- 
lofen were present, no specific [3H]GABA binding remained on the section. The dis- 
tributions of GABAB and GABAA receptor binding to human hippocampus were 
most prominent in the stratum moleculare of the dentate gyrus, stratum lacunosum- 
moleculare and stratum pyramidale of  CAt. Intermediate density of [3H]GABA bind- 
ing to the subiculum and dentate hilus, and negligible binding to white matter were 
observed (Fig. 1). There were roughly 3 times more GABAA than GABAB receptors 
in both control and DAT hippocampus. 
Specific binding of [3H]GABA to both GABAB and GABAA receptor sites was 
saturable after 45 min at 4°C. Analysis of the Scatchard plots did not disclose consis- 
tent differences in the Kd values between controls and DATs, but did reveal striking 
changes between the two groups in the Bm~x of  hippocampal [3H]GABA binding. No- 
tably, GABAB receptors in the DAT group were reduced by 50-70% relative to con- 
trois in stratum moleculare of dentate gyrus, stratum lacunosum-moleculare and 
stratum pyramidale of  CA1. Significant differences in Bm~x values of GABAA binding 
between DAT and controls were found only in stratum pyramidale of CAl. No sig- 
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nificant difference in Bma x values of GABAB nor GABAA binding was seen in the 
subiculum (Fig. 2). 
The overlapping distribution in GABAB and GABAA receptors in human hippo- 
campus may indicate that the targets of GABAB and GABAA innervation are similar. 
Fig. 1. Representative autoradiograms of [3H]GABA (20 nM) binding to human hippocampal sections 
from a control (left) and a DAT (right) brain. GABAA binding (top) was conducted in the presence of 
100/tM ( _+)-baclofen to block binding of [3H]GABA to GABAa sites. Conversely, GABAB binding (mid- 
dle) was conducted in the presence of 10/tM isoguvacine to block binding to GABAA sites. The corres- 
ponding Nissl-stained sections are shown on the bottom row. SMDG, stratum moleculare of dentate 
gyrus; SGDG, stratum granulosum of dentate gyrus; SML, stratum lacunosum-moleculare of CAt; SP, 
stratum pyramidale of CA~; SUB. subiculum; HF, hippocampal fissure; Wh, white matter; LGN, lateral 
geniculate nucleus. Bar = 0.5 cm. 
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The same local circuit GABAergic interneuron may elict postsynaptic membrane 
hyperpolarization via both GABAA and GABAB receptors. That there appear to be 
relatively more GABAA than GABAB receptors in hippocampus is also consistent 
with the electrophysiologic observation that GABAA-mediated mechanisms predom- 
inate in the hippocampus [5, 13]. Interestingly, the distribution of GABAA receptors 
in human hippocampus is in excellent agreement with that of benzodiazepine recep- 
tors [12]. Both show highest density of binding in dentate molecular layer and CAI 
pyramidal layer. The distribution of GABA receptors in hippocampus is also in ac- 
cordance with both the topography of GAD-positive [14] and GABA-immunoreac- 
tive terminals [6], and that of somatostatin receptors [17]. 
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Fig. 2. Histogram of Bmax values of GABAA (top) and GABAB (bottom) binding to control (open bars) 
and DAT (hatched bars) hippocampus. The mean Bmax values and S.E.M. values in pmol/mg protein 
represent the average of 6 control and 6 DAT subjects. Significant differences were determined by indepen- 
dent, two-tailed Student's t-statistic and by Mann-Whitney U-test. 
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The decreased density o f  G A B A a  and GABAA receptors in s t ratum lacunosum- 
moleculare and s t ra tum pyramidale o f  CA 1 region in D A T  hippocampal  format ion  
most  likely reflects the dendritic stunting and degeneration o f  pyramidal  cells in 
DAT.  This h ippocampal  region exhibits the highest density o f  neuritic plaques, tan- 
gles and granulovacuolar  degenerat ion in D A T  [l, 7, 9]. The selective loss o f  GABAB 
receptors in the dentate gyrus o f  D A T  h ippocampus  may reflect the observed pathol-  
ogy in this region. H y m a n  et al. [10] have noted neuritic plaque format ion in the 
molecular layer o f  dentate gyrus f rom D A T  hippocampus.  These plaques may  
involve dyst rophic  axons from entorhinal  cortical neurons and /or  degenerating den- 
drites o f  dentate granule cells [16]. The significant decline in GABAB receptors in this 
region may  be related to the presence o f  plaques in this layer. G A B A a  receptors in 
the dentate molecular  layer could exist on axon terminals f rom entorhinal cortical 
neurons or  on dendrites o f  the granule cells themselves. It is not  entirely clear whether 
the losses in GABAB receptors in D A T  reflect neurodegenerat ion ofen torh ina l  corti- 
cal or dentate granule cells. Studies in the rat suggest the latter case to be true. 
G A B A a  receptors in dentate molecular  layer are selectively spared after entorhinal 
cortical knife-cut lesions, but  are lost after colchicine-induced neurotoxici ty o f  gran- 
ule cells (Chu et al., in preparation).  The decrements in G A B A  receptors we have 
observed may  thus reflect and possibly contr ibute to the pathological  findings and 
clinical picture o f  memory  impairment  associated with DAT.  
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